Legius Syndrome

Overview

Legius syndrome is a genetic condition that causes some of the skin signs seen in neurofibromatosis type 1 (NF1), particularly multiple cafe-au-lait spots and freckling in skin folds. For this reason it is sometimes called an NF1-like syndrome. It is caused by changes in a gene called SPRED1.

The important distinction is that Legius syndrome is generally much milder than NF1. People with Legius syndrome do not develop the nerve tumors (neurofibromas) or many of the other complications associated with NF1. Because the skin signs can look identical at first, genetic testing is often needed to tell the two conditions apart, which has real implications for monitoring and reassurance.

Symptoms

The features of Legius syndrome are usually limited and mild. They can include:

• Several cafe-au-lait spots (flat, light-to-medium brown patches)
• Freckling in the armpits or groin
• Sometimes a larger head size than average
• In some people, mild learning or attention differences

Crucially, Legius syndrome does not cause the nerve tumors, eye findings, or bone and other complications that can occur in NF1. Because of this, the condition is generally not associated with the serious health problems linked to NF1, although the overlapping skin signs make professional evaluation important.

Causes

Legius syndrome is caused by a change (variant) in the SPRED1 gene. This gene helps regulate a signaling pathway that controls cell growth, the same general pathway affected in NF1, which is why the conditions share some skin features.

• Inherited: The condition follows an autosomal dominant pattern, meaning a child has a 50 percent chance of inheriting it if a parent carries the gene change.
• New gene change: In some people the change arises newly, without a family history.

Because the SPRED1 gene change affects the body more mildly than the NF1 gene change, the resulting condition is less severe.

Risk Factors

• Having a parent or close relative with Legius syndrome
• A family history of multiple cafe-au-lait spots without the tumors of NF1
• Being evaluated for NF1 features, which may lead to Legius syndrome being identified instead

Diagnosis

Because the skin signs overlap with NF1, careful evaluation is needed:

• Clinical examination: Counting cafe-au-lait spots and checking for freckling and any NF1 features.
• Genetic testing: Testing for a change in the SPRED1 gene confirms Legius syndrome and distinguishes it from NF1, which involves a different gene.
• Follow-up over time: The absence of nerve tumors and other NF1 features over time supports the diagnosis.

Distinguishing Legius syndrome from NF1 matters because it changes how closely a person needs to be monitored.

Treatment

Legius syndrome itself usually needs little or no specific treatment because it is mild and does not cause the complications of NF1. Care focuses on:

• Confirming the diagnosis: Genetic testing to separate Legius syndrome from NF1, which provides reassurance and avoids unnecessary monitoring.
• Supporting learning and attention: If a child has learning or attention differences, school support and tailored help can be valuable.
• Routine care: The cafe-au-lait spots and freckling are harmless and do not need treatment.
• Genetic counseling: Helping families understand inheritance and testing options.

Because serious complications are not expected, intensive surveillance is generally not required once the diagnosis is clear.

Prevention

Legius syndrome cannot be prevented because it is caused by a genetic change. Helpful steps include:

• Genetic counseling for families to understand inheritance and recurrence chances
• Confirming the diagnosis so children are not subjected to unnecessary NF1 monitoring
• Addressing any learning or attention needs early to support development

When to See a Doctor

Consider seeing a doctor if you or your child has:

• Multiple cafe-au-lait spots or freckling in skin folds, to clarify the diagnosis
• A family history of Legius syndrome or NF1
• Learning or attention difficulties that could benefit from support

While Legius syndrome is mild, evaluation is worthwhile mainly to confirm that the features are not due to neurofibromatosis type 1, which needs closer follow-up.

Related Topics

Frequently Asked Questions

References

1. National Organization for Rare Disorders (NORD). Legius Syndrome.
2. MedlinePlus, U.S. National Library of Medicine. Legius syndrome.
3. National Institute of Neurological Disorders and Stroke (NINDS). Neurofibromatosis.
4. Genetic and Rare Diseases Information Center (GARD). Legius syndrome.